ACM
DXCM icon

American Capital Management’s DexCom DXCM Stock Holding History

American Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Sell
235,152
-16,323
-6% -$1.09M 0.71% 39
2026
Q1 		$15.8M Buy
251,475
+2,701
+1% +$188K 0.85% 37
2025
Q4 		$16.5M Sell
248,774
-109,016
-30% -$7.05M 0.73% 37
2025
Q3 		$24.1M Buy
357,790
+2,217
+0.6% +$175K 0.96% 29
2025
Q2 		$31M Sell
355,573
-45,220
-11% -$3.54M 1.29% 28
2025
Q1 		$27.4M Buy
400,793
+94,789
+31% +$7.74M 1.11% 34
2024
Q4 		$23.8M Sell
306,004
-47,795
-14% -$3.54M 0.89% 38
2024
Q3 		$23.7M Sell
353,799
-3,007
-0.8% -$247K 0.78% 37
2024
Q2 		$40.5M Buy
356,806
+1,260
+0.4% +$159K 1.35% 27
2024
Q1 		$49.3M Sell
355,546
-7,842
-2% -$986K 1.58% 23
2023
Q4 		$45.1M Buy
363,388
+41,539
+13% +$4.24M 1.54% 22
2023
Q3 		$30M Buy
321,849
+31,238
+11% +$3.52M 1.16% 29
2023
Q2 		$37.3M Sell
290,611
-2,213
-0.8% -$268K 1.3% 25
2023
Q1 		$34M Buy
292,824
+10,207
+4% +$1.14M 1.2% 26
2022
Q4 		$32M Buy
282,617
+1,943
+0.7% +$213K 1.25% 25
2022
Q3 		$22.6M Sell
280,674
-894
-0.3% -$75.7K 0.89% 34
2022
Q2 		$21M Buy
281,568
+2,332
+0.8% +$213K 0.79% 34
2022
Q1 		$35.7M Buy
279,236
+7,376
+3% +$807K 1.05% 30
2021
Q4 		$36.5M Sell
271,860
-944
-0.3% -$136K 0.94% 33
2021
Q3 		$37.3M Sell
272,804
-2,816
-1% -$355K 1% 33
2021
Q2 		$29.4M Buy
275,620
+39,812
+17% +$3.82M 0.82% 34
2021
Q1 		$21.2M Buy
235,808
+61,800
+36% +$5.8M 0.64% 39
2020
Q4 		$16.1M Buy
174,008
+55,904
+47% +$4.99M 0.48% 42
2020
Q3 		$12.2M Buy
118,104
+1,728
+1% +$181K 0.45% 41
2020
Q2 		$11.8M Buy
116,376
+1,744
+2% +$156K 0.43% 44
2020
Q1 		$7.72M Buy
+114,632
New +$7.13M 0.38% 45

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

American Capital Management's DXCM Position: Q2 2026 in Review

American Capital Management reduced its DexCom (DXCM) stake by 6.5% in Q2 2026, selling an estimated $1.09M and leaving 235,152 shares worth $15.8M. The position accounts for 0.71% of the portfolio, ranked #39.

American Capital Management first reported a position in DXCM in Q1 2020 and has held it in 26 quarters since. The position peaked at $49.3M in Q1 2024. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • American Capital Management held 235,152 shares of DexCom worth $15.8M as of Q2 2026.
  • American Capital Management sold 16,323 DexCom shares in Q2 2026, an estimated $1.09M.
  • DexCom made up 0.71% of American Capital Management's portfolio in Q2 2026, its #39 holding.
  • American Capital Management first reported a position in DexCom in Q1 2020 and has held it in 26 quarters since.
  • American Capital Management's DexCom position peaked at $49.3M in Q1 2024.
  • 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on American Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.